Stock Price Quote

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE1522.555.4 (+0.36 %)
PREV CLOSE ( ) 1517.15
OPEN PRICE ( ) 1505.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 145686
TODAY'S LOW / HIGH ( )1502.15 1528.90
52 WK LOW / HIGH ( )922.55 1638.7
NSE1522.806.4 (+0.42 %)
PREV CLOSE( ) 1516.40
OPEN PRICE ( ) 1505.00
BID PRICE (QTY) 1522.80 (296)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2536516
TODAY'S LOW / HIGH( ) 1503.70 1528.30
52 WK LOW / HIGH ( )922.45 1638.85
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1993
Management Info
- Chairman Dilip S Shanghvi - Managing Director
Registered Office

Address Sun Pharma Advanced Research Centre (S P A R C),Tandalja,,
Vadodara,
Gujarat-390020

Phone 0265- 5515500 / 5515600 / 5515700

Email secretarial@sunpharma.com

Website www.sunpharma.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

12Apr USFDA issues OAI status to Sun Pharmac
US Food and Drug Administration (USFDA) has issued Official Action Indic..
28Mar Clarification sought from Sun Pharmac
The Exchange has sought clarification from Sun Pharmaceutical Industries..
23Mar Sun Pharmaceutical Industries informs
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..
19Mar Sun Pharmaceutical Industries informs
Sun Pharmaceutical Industries has informed that it enclosed a copy of th..
16Mar Sun Pharmaceutical Industries informs
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit7213.116907.2
Gross Profit 7514.7 17410.5
Operating Profit 1435867518.9
Net Sales 50737.5208121.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1455.20 (10.00%)
M.Cap ( in Cr)846.88
Solara Active Pharma (BSE)
peergroup  551.45 (16.32%)
M.Cap ( in Cr)1985.01
Abbott India (BSE)
peergroup  26131.85 (0.29%)
M.Cap ( in Cr)55528.36
Windlas Biotech (BSE)
peergroup  555.05 (6.97%)
M.Cap ( in Cr)1154.42
Concord Biotech (BSE)
peergroup  1595.25 (1.05%)
M.Cap ( in Cr)16688.90

Shareholding Pattern

NON-INSTITUTION 8.97%
PROMOTERS 54.48%
FI/BANKS/INSURANCE 5.12%
MUTUAL FUNDS/UTI 12.21%
GOVERNMENT 0%
FII 0%

About Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. was incorporated in the year 1993. Its today's share price is 1522.55. Its current market capitalisation stands at Rs 365310.75 Cr. In the latest quarter, company has reported Gross Sales of Rs. 217721.3 Cr and Total Income of Rs.211414.3 Cr. The company's management includes Rolf Hoffmann, Sanjay Asher, Rama Bijapurkar, Gautam Doshi, Sudhir V Valia, Aalok Shanghvi, Dilip S Shanghvi, Pawan Goenka, Anoop Deshpande.

It is listed on the BSE with a BSE Code of 524715 , NSE with an NSE Symbol of SUNPHARMA and ISIN of INE044A01036. It's Registered office is at Sun Pharma Advanced Research Centre (S P A R C),Tandalja,Vadodara-390020, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, Price Waterhouse, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.